发明名称 CODON OPTIMIZED SYNTHETIC PLASMIDS
摘要 One aspect of the current invention is an optimized synthetic mammalian expression plasmid (e.g. pAV0201). This new plasmid comprise a therapeutic element, and a replication element. The therapeutic element of the new plasmid comprises a eukaryotic promoter; a 5' untranslated region ("UTR"); a codon-optimized-eukaryotic therapeutic gene sequence; and a poly adenylation signal. The therapeutic elements of this plasmid are operatively linked and located in a first operatively-linked arrangement. Additionally, the optimized synthetic mammalian expression plasmid comprises replication elements, wherein the replication elements are operatively linked and located in a second operatively-linked arrangement. The replication elements comprise a selectable marker gene promoter, a ribosomal binding site, and an origin of replication. The first-operatively-linked arrangement and the second-operatively-linked arrangement comprise a circular structure of the codon optimized synthetic mammalian expression plasmid.
申请公布号 US2008194511(A1) 申请公布日期 2008.08.14
申请号 US20070941876 申请日期 2007.11.16
申请人 VGX PHARMACEUTICLAS, INC. 发明人 DRAGHIA-AKLI RUXANDRA;ABRUZZESE RONALD V.;KERN DOUGLAS R.
分类号 A61K31/711;A61K48/00;C07K14/60;C12N15/67;C12N15/85 主分类号 A61K31/711
代理机构 代理人
主权项
地址